Tissue Diagnostics Market Size
Market Overview
Tissue diagnostics is analyzing and evaluating particular tissue samples in order to understand the biological background of illnesses. They are used to detect specific medical problems including as cancer and inflammatory illnesses, as well as indicate the precise kind and degree of malignancy, which aids in the identification of probable causes and treatment choices. Tissue diagnostics are very accurate, low-cost, and may be done using a variety of procedures, including core and open biopsy. These diagnoses are now performed using modern technologies such as immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special labelling. The disease insights and factors that influence patient outcomes are captured by tissue diagnostics. Tissues, in general, provide for individualized diagnosis and therapy. The majority of samples are made up of tissue fragments collected through various procedures. Small biopsies and huge specimens extracted during surgery are examples. Other important factors driving the market's growth are rising healthcare expenditures and technical developments in tissue diagnostics.
Tissue Diagnostics Market: Key Players
-
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
- Agilent Technologies Inc.
- BioGenex Laboratories
- Cancer Genetics Inc.
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Genomic Health Inc.
- Merck KGaA
- Thermo Fisher Scientific.
- Bio Rad
- Biomeriux
Growth Factor
Increased cancer patients
The number of persons diagnosed with cancer has increased as a result of changing lifestyles, increased cigarette and alcohol intake, and rising incidence of lifestyle problems. The need for tissue diagnostics in the treatment of breast cancer, prostate cancer, and other cancers is propelling the market during the forecast period, owing to a growth in the population and an increase in chronic illnesses throughout the world.
Segmentation
- By Product
- Instruments
- Reagents & Consumables
- By Technology
- Immunohistochemistry
- In-Situ Hybridization
- Digital Pathology & Workflow Management
- Others
- By Disease
- Breast Cancer
- Prostate Cancer
- Gastric Cancer
- Other Cancers
- By End-User
- Hospitals
- Research Laboratories
- Pharmaceutical Companies
- Contract Research Organizations
- Others
- Tissue Diagnostics Market Dynamics
- Tissue Diagnostics Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Recent News Related to Market
-
In 2019, Roche and GE Healthcare have agreed to collaborate on the development of an integrated digital diagnostics platform aimed at improving cancer and critical care therapy.
-
In 2019, Hologic received CE permission for ThinPrep Genesis Processor.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- What is the Tissue Diagnostics Market growth?
- Which segment accounted for the largest Tissue Diagnostics Market share?
- Who are the key players in the Tissue Diagnostics Market?
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Frequently Asked Questions (FAQ):
Tissue diagnostics market encompasses technologies and solutions that analyse biological tissue samples for disease detection and treatment guidance. It includes instruments, reagents and consumables used in methods like immunohistochemistry, in situ hybridisation and digital pathology for applications such as cancer diagnosis, personalized medicine and research.
Global tissue diagnostics market was valued at around USD 8.72 billion in 2024 and is projected to reach roughly USD 14.03 billion by 2030, reflecting a compound annual growth rate (CAGR) of about 8.4%.
Key growth drivers include a rising prevalence of cancer and chronic diseases, growing demand for early and accurate diagnostics, increasing adoption of digital pathology and software-driven workflows, and expanding investment in precision medicine and biomarker-based testing.
Challenges include high cost of advanced diagnostic systems, need for skilled personnel and infrastructure, stringent regulatory and validation requirements, and variability in reimbursement and adoption across different healthcare settings.
Market is typically segmented by technology (e.g., immunohistochemistry, in-situ hybridization), by application (e.g., breast cancer, lung cancer, other indications), by end-use (hospitals, diagnostic labs) and by region (North America, Europe, Asia-Pacific, etc.).
Select License Type
.png){kind=icon}
